TOPOTARGET A/S 
By To NASDAQ OMX Copenhagen A/S
Announcement no. 13-11 / Copenhagen, 3 August 2011
Notice to Convene Extraordinary General MeetingNotice is hereby given that an extraordinary general meeting of Topotarget A/S will be held on:
29 August 2011 at 12.00 CET.The extraordinary general meeting will be held at:
SymbionFruebjergvej 3DK-2100 Copenhagen ØThe items on the agenda for the extraordinary general meeting will be
1. Election of board members and 2. Authority to the chairman of the extraordinary general meetingRe. 1 - Election of board membersThe purpose of the extraordinary general meeting is the election of two additional members of the board of directors. The board of directors has concluded a process of identifying additional board members and are happy to be able to propose election of Dr. Gisela Schwab and Dr. Karsten Witt to the board. Both are proposed to be elected for a period until the next annual general meeting in the Company. None of the members of the board of directors will resign in connection with the election.
Dr. Gisela Schwab is Executive Vice President Development and Chief Medical Officer at Exelixis, Inc., South San Francisco, US. Prior to joining Exelixis, Inc. in the year 2006 Dr. Schwab served as Senior Vice President and Chief Medical Officer at Abgenix Inc., Fremont, US and was employed in several positions at Amgen, Inc., US following their acquisition of Abgenix. Dr. Schwab is Doctor of Medicine from University of Heidelberg with Board Certification in Internal Medicine and Hematology/Oncology. She has great experience within the pharmaceutical industry in managing early and late stage development activities (target selection, preclinical, pharmacokinetic, clinical and regulatory development) of biotechnological compounds and small molecules, leading to worldwide product registration (17+ years experience). Furthermore she holds great experience in filing of INDs and BLAs/MAAs and in building and managing development teams ranging from several to150+ people. Dr. Schwab is presenter and author of numerous preclinical and clinical study results and book chapters.
Topotarget A/S
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel.: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-no.: 25695771
www.topotarget.comPage 1 of 4
Notice to Convene Extraordinary General Meeting
Dr. Karsten Witt was until recently Sr. Vice President Pharmaceutical Operations at OSI Pharmaceuticals, Inc., Melville, US, which he joined in 2002. Here he was intimately involved in the development of small-molecule targeted oncology therapies including the EGFR inhibitor Tarceva® (erlotinib) which is being co-developed with Roche and Genentech. Dr. Witt served as a member of the Tarceva Tripartite Global Development Committee since2007. Prior to joining OSI Pharmaceuticals, Inc., he served as Sr. Director of Clinical Research
& Drug Safety at NeXstar Pharmaceuticals and Gilead Sciences Inc. Dr. Witt is Doctor of Medicine from University of Copenhagen. He has been involved in successful filing of 6 oncology INDs, 3 lung cancer filings and one filing for pancreatic cancer all leading to approval by the FDA and EMA, as well as 2 BLA/sBLA filings for hepatitis C, and one NDA for hepatitis B resulting in regulatory approvals in the US and Europe. Dr. Witt is presenter and author of numerous publications.Re. 2 - Passing of a resolution giving authority to the chairman of the general meetingThe board of directors proposes that the chairman of the meeting or a substitute duly appointed by him be authorised to apply for registration of the resolutions passed and to make any such amendments thereto as may be required by the Danish Commerce and Companies Agency as a condition for registration or approval.
--oo0oo-- The adoption of the board of directors’ proposals are adopted by a simple majority of the votes cast. The Company's nominal share capital currently amounts to DKK 132,652,050 consisting of 132,652,050 shares of DKK 1 nominal value each. At general meetings, each share amount of DKK 1 nominal value carries one vote. The shareholders exercise their financial rights through their own deposit banks.Information: The following information is available at the Company's website www.topotarget.com as of 3 August 2011:
